Warning: dir(/opt/bitnami/wordpress/wp-content/upgrade/wordpress-seo.25.2/wordpress-seo/src/introductions/infrastructure/): Failed to open directory: No such file or directory in /opt/bitnami/wordpress/wp-admin/includes/class-wp-filesystem-direct.php on line 636

Warning: dir(/opt/bitnami/wordpress/wp-content/upgrade/wordpress-seo.25.2/wordpress-seo/src/introductions/user-interface/): Failed to open directory: No such file or directory in /opt/bitnami/wordpress/wp-admin/includes/class-wp-filesystem-direct.php on line 636

Warning: dir(/opt/bitnami/wordpress/wp-content/upgrade/wordpress-seo.25.2/wordpress-seo/src/user-meta/domain/): Failed to open directory: No such file or directory in /opt/bitnami/wordpress/wp-admin/includes/class-wp-filesystem-direct.php on line 636

Warning: dir(/opt/bitnami/wordpress/wp-content/upgrade/wordpress-seo.25.2/wordpress-seo/src/user-meta/framework/custom-meta/): Failed to open directory: No such file or directory in /opt/bitnami/wordpress/wp-admin/includes/class-wp-filesystem-direct.php on line 636
Negative News Screening (Adverse Media Screening) for DR REDDYS LAB

DR REDDYS LAB

Location

South Carolina

Founded

2010-04-27

Risk Signals

2 news mentions monitored

Industry Context

This company is tracked across risk categories, including those related to its sector (e.g., Nonclassifiable Establishments), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.

Filter risk signals by topic

Select a theme below to explore the company’s news mentions in specific risk areas.

Recent Articles about DR REDDYS LAB

Live alerts from global media, monitored by Business Radar

Pharma sector Q1 review: Growth led by US market, gRevlimid sales; India growth slips on price cuts, muted volumes

2023-08-28 (financialexpress.com)

Pharma sector Q1 review: Growth led by US market, gRevlimid sales; India growth slips on price cuts, muted volumes

"Growth in domestic pharmaceutical revenues of all the major companies will be moderate. Lower RM prices and easing US generic pricing conditions will lead to higher gross and EBITDA margins. Net profits of the pharmaceutical companies are likely to grow 14 per cent in FY24 and 18 per cent in FY25."

Read more

Never miss a headline about DR REDDYS LAB

Set up smart alerts with Business Radar and receive real-time updates on any new risk signal or major news story.

  • ✔️ Used by 100+ compliance teams and analysts
  • ✔️ Covers 154M+ sources in 40+ languages